Adenoviruses encoding HPRT correct biochemical abnormalities of HPRT-deficient cells and allow their survival in negative selection medium.
The Lesch-Nyhan syndrome is an X-linked disorder caused by a virtually complete absence of the key enzyme of purine recycling, hypoxanthine-guanine phosphoribosyltransferase (HPRT). It is characterized by uric acid overproduction and severe neurological dysfunction. No treatment is yet available for the latter symptoms. A possible long-term solution is gene therapy, and recombinant adenoviruses have been proposed as vectors for gene transfer into postmitotic neuronal cells. We have constructed an adenoviral vector expressing the human HPRT cDNA under the transcriptional control of a short human cytomegalovirus major immediate early promoter (RAd-HPRT). Here we show that infection of human 1306, HPRT-negative cells with RAd-HPRT, expressed high enough levels of HPRT enzyme activity, as to reverse their abnormal biochemical phenotype, thus enhancing hypoxanthine incorporation and restoring purine recycling, increasing GTP levels, decreasing adenine incorporation, and allowing cell survival in HAT medium in which only cells expressing high levels of HPRT can survive. Infection of murine STO cells, increased hypoxanthine incorporation and restored purine recycling, thus allowing cell survival in HAT medium, and reduced de novo purine synthesis. Although both cells were able to survive in HAT medium post infection with RAd-HPRT, some of the biochemical consequences differed. In summary, even though adenoviral vectors do not integrate into the genome of target HPRT-deficient human or murine cells, RAd-HPRT mediated enzyme replacement corrects abnormal purine metabolism, increases intracellular GTP levels, and allows cells to survive in a negative selection medium.
Southgate
T D
TD
Molecular Medicine and Gene Therapy Unit, School of Medicine, University of Manchester, England.
Bain
D
D
Fairbanks
L D
LD
Morelli
A E
AE
Larregina
A T
AT
Simmonds
H A
HA
Castro
M G
MG
Löwenstein
P R
PR
D000225:Adenine / Q000378:metabolism / Q000494:pharmacology; D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002250:Carbon Radioisotopes; D002470:Cell Survival / Q000187:drug effects* / Q000502:physiology*; D002478:Cells, Cultured / Q000187:drug effects / Q000201:enzymology; D003470:Culture Media; D003587:Cytomegalovirus / Q000235:genetics; D018076:DNA, Complementary / Q000235:genetics; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D017781:Genes, Immediate-Early / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000494:pharmacology*; D005998:Glycine / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D019271:Hypoxanthine / Q000378:metabolism / Q000494:pharmacology; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency* / Q000235:genetics*; D007926:Lesch-Nyhan Syndrome / Q000503:physiopathology / Q000628:therapy; D051379:Mice; D011401:Promoter Regions, Genetic; D012265:Ribonucleotides / Q000378:metabolism; D013997:Time Factors; D014158:Transcription, Genetic / Q000235:genetics
D002250:Carbon Radioisotopes; D003470:Culture Media; D018076:DNA, Complementary; D012265:Ribonucleotides; D019271:Hypoxanthine; D007041:Hypoxanthine Phosphoribosyltransferase; D000225:Adenine; D005998:Glycine